Long-term effectiveness and tolerability of apremilast in patients with moderate-to- severe plaque psoriasis: A 5-year multicentre retrospective study—IL PSO (Italian landscape psoriasis)

Apremilast is an oral inhibitor of phosphodiesterase (PDE)-4 that has been approved for the treatment of patients with moderate-to- severe plaque psoriasis who have contraindications or inadequate response to conventional systemic treatments. 1,2 It is also indicated for the management of adults with active psoriatic arthritis (PsA) who have failed or are intolerant to other disease-modifying antirheumatic drugs (DMARDs).1,2 In Italy, apremilast is reimbursed for patients with moderate-to- severe plaque psoriasis in case of inadequate response/intolerance to systemic treatments and those with contraindications to biological drugs.3 Despite the wide use of apremilast for the treatment of plaque psoriasis, long-term real-world experiences are still limited.4,5